Visualization of FISH Probes by Dual-Color Chromogenic In Situ Hybridization
Authors:
- Jan T. JørgensenJan T. Jørgensen
- Sven MüllerSMSven Müller
- Ole RasmussenOROle Rasmussen
- Andreas SchønauASAndreas Schønau
Open Access
- 1 February 2010
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 133 (2) , 205-211
Abstract
The overall purpose of the study was to demonstrate applicability of the DAKO dual-color chromogenic in situ hybridization (CISH) assay (DAKO Denmark, Glostrup) with respect to 4 fluorescence in situ hybridization (FISH) probes: MYC (c-MYC), EGFR, ERBB2 (HER2), and TOP2A. The study showed that the dual-color CISH assay can convert Texas red and fluorescein isothiocyanate (FITC) signals into chromogenic signals with an almost complete 1:1 conversion ratio. Agreement studies between the FISH assays for HER2 and TOP2A and the corresponding CISH conversion assays showed 100% concordance (κ values of 1.0) between the CISH and FISH methods for HER2 and TOP2A status. The correlations of the gene copy number to centromere-17 ratios were similarly high, with a correlation coefficient (r) for HER2 and TOP2A of more than 0.95. Owing to the relatively small number of specimens in this study, it is important that the data are confirmed in a larger study.Keywords
This publication has 11 references indexed in Scilit:
- Novel horseradish peroxidase substrates for use in immunohistochemistryJournal of Immunological Methods, 2009
- The value ofTOP2Agene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89DActa Oncologica, 2008
- Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American PathologistsVirchows Archiv, 2007
- Pharmacodiagnostics and Targeted Therapies—A Rational Approach for Individualizing Medical Anticancer Therapy in Breast CancerThe Oncologist, 2007
- Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancerJournal of Clinical Pathology, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep®-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab EraThe Oncologist, 2006
- Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibilityLaboratory Investigation, 2005
- Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancerJournal of Molecular Histology, 2004
- Chromogenic in Situ HybridizationThe American Journal of Pathology, 2000